In the treatment of breast cancer, endocrine therapy is the oldest and one of the most commonly used methods among various treatments other than surgery. The mechanism of action of endocrine therapy is different from chemotherapy, and its side effects are less than chemotherapy, with longer maintenance time and better quality of life for patients. Breast cancer is a hormone-dependent tumor, regulated by estrogen and progesterone. The application of endocrine therapy has a better effect in cases with positive estrogen or progesterone receptors, while the effect is poor in ER and PR negative cases; therefore, endocrine therapy is generally not considered for those with negative hormone receptors. If the previous endocrine therapy is effective for tumor and the disease progresses again, the efficiency is still higher if the treatment is changed to other endocrine drugs. The selection of endocrine drugs is based on the patient’s age, lesion site, interval between surgery and recurrence and receptor determination, in addition to the mechanism of action of different drugs and side effects. The following points can be used for reference when choosing endocrine therapy: 1. Triamcinolone acetonide can be preferred, whether premenopausal or postmenopausal. After 5 years, if you are menopausal, you can apply aromatase inhibitor for 2-5 years, and the effect will be better. 2.For post-menopausal families with good economic status, it is recommended that aromatase inhibitors are preferred and applied for at least 2-5 years. 3, pre-menopausal high-risk patients, such as the economic situation allows, can first choose the “double German” therapy (i.e., the combination of Norad and Renindezvous), the effect is better than triamcinolone. If the tumor recurs or metastasizes during the application of triamcinolone or other endocrine drugs, or the disease progresses, another type of endocrine therapeutic drug can be used instead. 5.Progestins are used as second-line drugs, mainly for those with advanced breast cancer and other endocrine drugs have failed, especially for those with cachexia. Endocrine therapy is usually administered sequentially after the end of radiotherapy and chemotherapy, and usually not in combination with radiotherapy and chemotherapy. Endocrine therapy alone can be considered for certain elderly recurrent and metastatic breast cancers.